Unlocking the potential of organ-on-a-chip technology
In the Netherlands organ-on-a-chip (OoC) is seen as a promising new technology, since it can transform drug development by replicating the key functions of human organs on a microfluidic chip. This animal-free technology has the potential to transform the Life Sciences & Health sector. It is expected that it will contribute to sustainable and structural economic growth, improved drug development and most importantly, improved quality of life. This aligns with the broader ambition to strengthen the Dutch Life Sciences & Health ecosystem and improve patients’ quality of life.
By mimicking the essential functions of human organs on a microfluidic chip, this technology has the potential to significantly improve drug development. These chips, made from flexible and transparent materials, contain microscopic channels where human cells grow into 3D structures that simulate real organ behavior. This enables more accurate predictions of drug efficacy and toxicity, reduces the need for animal testing, and speeds up the development of safer and more effective treatments. With ongoing advancements such as multi-organ systems and personalized models, OoC is a key enabler of precision medicine.
Commissioned by the Ministry of Foreign Affairs, Health~Holland, the Netherlands Enterprise Agency (RVO), the Ministry of Economicy Affairs, the Dutch Embassy in Switzerland, and the life sciences & health industry have joined forces to establish a strategic collaboration aimed at advancing the adoption and international positioning of Organ-on-Chip (OoC) technologies. This initiative has resulted in an approved Strategic Multi-Year Market Development Plan (2026-2028), also referred to as a ‘roadmap’, to strengthen cooperation between the Netherlands and Switzerland and to position both countries as global leaders in the field of Organ-on-Chip.
In the coming years (2026 - 2028), multiple initiatives and programs will be launched to further strengthen the national and international Organ-on-Chip ecosystem. Together, these activities contribute to the strategic positioning of the Netherlands (as well as Switzerland and Europe) within the global landscape of medical and biomedical innovation. By connecting these initiatives, we create a coherent, multi-year approach that not only accelerates technological development but also enhances international visibility and strengthens the geopolitical position of both countries. Stay up-to-date on the planned activities through our event page!
Market study
In 2025, the market study "Swiss Organ-on-Chip Landscape & Opportunities for Dutch-Swiss Collaboration" was published. Commissioned by the Embassy of the Netherlands and conducted by Trilliome, the study outlines key recommendations for collaboration opportunities relevant to Dutch stakeholders.
Have a look at the market study here
Our ambitions
Our vision
To position the Netherlands as an international hub for organ-on-a-chip technology—comparable to ASML’s role in the semiconductor industry. By building sustainable bilateral partnerships with Switzerland, we aim to strengthen international competitiveness and unlock access to the Swiss pharmaceutical market.
Upcoming activities on organ-on-a-chip:
Want to stay up to date on organ-on-a-chip activities and developments in the Netherlands?
Make sure to follow our LinkedIn account so you don’t miss an activity.
Get in touch
Do you work on organ-on-a-chip technology or are you an early adopter looking to implement it in your drug development process? Do you want more information, collaborate or do you have a question? Please contact Laura: windt@health-holland.com .
